CD8A and cancer: One strategy involves using cancer-testis/cancer-germline antigens such as NY-ESO-1, which are proteins aberrantly expressed in OC, and have demonstrated consistent CD4+ and CD8+ T-cell responses in OC patients leading to prolonged responses (253, 254).